Study helps compare risks of treatments for early esophageal cancer

(Press-News.org) CHICAGO – A new study, published in the July, 2014, issue of the Journal of the National Cancer Institute by Northwestern Medicine® researchers, sheds new light on the risks associated with the growing popularity of endoscopic resection in the treatment of localized, early-stage esophageal cancer. Researchers found that the more traditional surgical resection, while more invasive, provided significantly better outcomes with an 87.6 percent five-year survival rate for patients than endoscopic resection, which had a 76 percent five-year survival rate. The study, "Treatment Trends, Risk of Lymph Node Metastasis, and Outcomes for Localized Esophageal Cancer," reviewed the outcomes of more than 5,000 patients from 824 hospitals using the National Cancer Data Base, a program of the American College of Surgeons Commission on Cancer and the American Cancer Society.

Endoscopic esophageal resection uses an endoscope, a flexible tube equipped with a small camera, which can be guided to very specific locations within the gastrointestinal tract with little or no disruption to the rest of the body. Esophageal surgical resection is used to remove a section of a patient's esophagus, and the digestive tract is then reconstructed by reconnecting the remaining unaffected sections.

"Endoscopic resection was becoming a more and more common surgical choice for treating early-stage esophageal cancer, but there really wasn't a single large study with evidence to suggest it was the best choice," said the senior author of the study, David J. Bentrem, MD, director of the Gastrointestinal Oncology Lab at Northwestern Memorial Hospital and Method professor of surgical research for the Northwestern University Feinberg School of Medicine. "This study sheds some much needed light on the issue and will hopefully encourage physicians and patients to more closely examine whether or not endoscopic resection is the best course of treatment."

In addition to reviewing survival rates, the study found that despite the lack of strong evidence-based research to promote a growing use of endoscopic esophageal resection, the procedure increased from 19 percent in 2004 to 53 percent in 2010 for T1a cancers and from 6.6 percent in 2004 to 20.9 percent in 2010 for T1b cancers. While both stages of esophageal cancer involve tumors that are close to the surface and relatively small, T1a esophageal tumors are the closer to the surface and less mature than those classified as T1b. The study's authors also state that most likely due to these differences, they also found that roughly one in five T1b cancers had spread to at least one lymph node, whereas only one in twenty T1a cancers had done the same.

"We know that for most patients with precancerous changes in the esophagus, endoscopy is the appropriate choice," said co-author Rajesh N. Keswani, MD, a Northwestern Medicine interventional gastroenterologist and assistant professor at the Feinberg School. "Our study suggests that patients with low risk T1a cancer can also be treated appropriately and safely with endoscopic resection when performed by a skilled endoscopist. However it also provides strong evidence that endoscopic treatment should only be offered to patients with more unfavorable T1b tumors that are likely to have spread when surgical resection is not a safe option."

"This is the largest study to date to compare endoscopic and surgical treatments for localized, early-stage esophageal cancer, and it helps compare the effectiveness of these two treatments," said co-author Karl Y. Bilimoria, MD, MS, a Northwestern Medicine surgical oncologist and director of the Surgical Outcomes and Quality Improvement Center at the Feinberg School. "Our findings make it clear that that physicians should only offer endoscopic resection to a patient following a discussion about their specific case between an expert endoscopist, surgeon, pathologist and oncologist to make sure it really is the best treatment option."

INFORMATION:

The study was funded by the Northwestern University Robert H. Lurie Comprehensive Cancer Center's Northwestern Institute for Comparative Effectiveness Research (NICER) in Oncology, an initiative of the William W. Wirtz cancer innovation fund. Bentrem, Keswani and Bilimoria are all members of the Lurie Cancer Center. NICER in Oncology is a multidisciplinary collaborative research program that focuses on comparative effectiveness and health policy in oncology.

To learn more about treatment for esophageal and other localized cancers, call 312-926-0779 or visit our website: http://hemonc.nm.org/?utm_source=nmh.org%2Fnm%2Fhematology-oncology-cancer-treatment&utm_medium=301re&utm_campaign=hemonc.

About Northwestern Medicine®

Northwestern Medicine® is the collaboration between Northwestern Memorial HealthCare and Northwestern University Feinberg School of Medicine around a strategic vision to transform the future of healthcare. It encompasses the research, teaching and patient care activities of the academic medical center. Sharing a commitment to superior quality, academic excellence and patient safety, the organizations within Northwestern Medicine comprise more than 9,000 clinical and administrative staff, 3,100 medical and science faculty and 700 students. The entities involved in Northwestern Medicine remain separate organizations. Northwestern Medicine is a trademark of Northwestern Memorial HealthCare and is used by Northwestern University.

About Northwestern Memorial Hospital

Northwestern Memorial is one of the country's premier academic medical center hospitals and is the primary teaching hospital of the Northwestern University Feinberg School of Medicine. Along with its Prentice Women's Hospital and Stone Institute of Psychiatry, the hospital has 1,705 affiliated physicians and 6,769 employees. Northwestern Memorial is recognized for providing exemplary patient care and state-of-the art advancements in the areas of cardiovascular care; women's health; oncology; neurology and neurosurgery; solid organ and soft tissue transplants and orthopaedics.

Northwestern Memorial has nursing Magnet Status, the nation's highest recognition for patient care and nursing excellence. Northwestern Memorial ranks 10th in the nation in the U.S. News & World Report 2014-15 Honor Roll of America's Best Hospitals. The hospital is recognized in 14 of 16 clinical specialties rated by U.S. News and is No. 1 in Illinois and Chicago in U.S. News' 2014-15 state and metro rankings, respectively. For 14 years running, Northwestern Memorial has been rated among the "100 Best Companies for Working Mothers" guide by Working Mother magazine. The hospital is a recipient of the prestigious National Quality Health Care Award and has been chosen by Chicagoans as the Consumer Choice according to the National Research Corporation's annual survey for 15 consecutive years.